Abciximab

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Definition
This section has been translated automatically.

Abciximab is a chimeric Fab fragment of a chimeric antibody of mice and humans against glycoprotein IIb/IIIa receptors. Abciximab binds with high affinity to activated forms of the receptor, thereby reducing fibrinogen binding to the secretory function of platelets.
The binding of Abciximab to the receptors is irreversible.

Indication
This section has been translated automatically.

Approval for the treatment of unstable angina pectoris and for coronary interventions

Dosage and method of use
This section has been translated automatically.

Initially 0.25 mg/kg body weight, then 0.125 ug/kg/min over 12 hours.
Dose adjustment for liver and kidney failure.

Contraindication
This section has been translated automatically.

Severe renal insufficiency

Preparations
This section has been translated automatically.

ReoPro®

Literature
This section has been translated automatically.

  1. HA Neumann (2014) The coagulation system. ABW-Scientific Publisher GmbH Berlin

Last updated on: 29.10.2020